Katy Beckermann, Medical Director of GU Clinical Research at Tennessee Oncology, shared on X:
“High-risk prostate cancer on RT plus 2 yrs of ADT: 2 yrs of enzalutamide did no better than 6 months of an older NSAA. ENZARAD, n=802, 92-mo follow-up.
- 8-yr MFS: 74% enza vs 72% NSAA, HR 0.88, p=0.34
- 8-yr OS: 83% enza vs 80% NSAA, HR 0.87
- Planned pelvic nodal RT subgroup, n=324: MFS HR 0.47 favoring enza
Nodal RT was required for cN1, optional for cN0, so it wasn’t randomized.
Negative overall. Read with STAMPEDE and DASL-HiCaP, my take is N1 disease needs intensification.”
Title: ENZARAD (ANZUP 1303): Phase III Trial of Enzalutamide With Androgen Deprivation Therapy and Radiation Therapy in High-Risk Localized or Locally Advanced Prostate Cancer
Authors: Scott Williams, Christopher J. Sweeney, Hayley Thomas, Blossom Mak, Alison Zhang, Tee Sin Lim, Chakiath Jose, Jarad Martin, Nitya Patanjali, David Pryor, Phuong Tran, Stephen Mangar, Alina M. Mihai, Carys Thomas, Simon Gampenrieder, Sonia Yip, Leanna Cheung, Sandra Lee, Annabelle Goodwin, Annette Haworth, Anna Walsh, Paul J. Kelly, Simon Hughes, Andrew Martin, Ray McDermott, Martin Stockler, Ian D. Davis, Paul L. Nguyen
You can also read: